Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

The No. 1 Pharma Stock to Buy for the Long Haul

Despite lingering macro disruptions, Street analysts expect pharma stock Pfizer (PFE) to gain double digits in the near term. Moreover, it pays a reliable dividend. Given its robust fundamentals, I think PFE might be an ideal buy for the long haul. Keep reading.

StockNews.com

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment.

Investors Business Daily

FDA panel weighs moving opioid antidote over the counter

U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Prepping for a new post-Roe reality

A decision on a lawsuit in Texas could lead to nationwide mifepristone ban

Salon

Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount

Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.

Investors Business Daily

The administration's next crack at lower drug prices

The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs.

Axios

Edinburgh-based health tech company Clevermed acquired by hospital software specialist System C

Move will support growth of flagship product BadgerNet,

Insider UK

Read news from The Economist, FT, and more,
with one subscription

CSL grows first-half profit 10pct to $2.6 billion

CSL has beaten first-half earnings expectations thanks to its vaccine business and contributions from its new iron deficiency therapy company.

AAP

Biotech's Drug Pipeline Expands From Melanoma To Other Cancers

Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March.

Investors Business Daily

The Best Stock to Invest $1,000 in Right Now

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

StockNews.com

Moderna Stock Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?

Investors Business Daily

AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected

AbbVie stock won at least one upgrade Friday after issuing long-awaited guidance for Humira for the first year it faces new competition.

Investors Business Daily

40 million would lose abortion access if court blocks pill, study shows

163% more women would lose access to abortion care if the FDA's approval of mifepristone is revoked.

Axios

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

Centene Corp. settles for $215 million on California Medicaid overbilling accusations

More than 20 states are investigating or have investigated Centene’s Medicaid pharmacy billing. The company also has agreed to pay settlements to at least 16 other states, including Illinois and Indiana.

Newsroom.co.nz

Pharmac to get one-time $66m boost

The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash injection, according to documents reviewed by Newsroom.

Investors Business Daily

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

AbbVie Rises As Lagging Profit Outlook Better Than Feared In Humira Battle Year

AbbVie stock inched higher Thursday after the company reported mixed earnings and issued a light profit outlook.

Get all your
news in one place.

100’s of premium titles.
One news app.

Birmingham Post

Shield Therapeutics revenues boosted by US sales of iron deficiency pills

The pharmaceuticals firm recently joined forced with Pennsylvania-based Viatris to tackle the American market

Investors Business Daily

Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket

Bayer stock surged to an eight-month high Wednesday after the company named former Roche exec Bill Anderson as its new chief executive.

Investors Business Daily

How IBD Stock Of The Day Inspire Medical Systems Won A Breakout

Inspire is Wednesday's IBD Stock Of The Day. The sleep apnea expert reported massive sales growth, leading shares to break out.

Investors Business Daily

Teva Guides To Its First Year Of Growth Since 2017 — But Shares Tumbled On This Caveat

Teva expects 2023 sales to grow for the first time in six years, but the guidance comes with one notable caveat and Teva stock fell.

Chicago Sun-Times

CVS buys Chicago-based Oak Street Health for $10.6B

Oak Street Health runs primary care centers mostly for lower-to-middle income people with Medicare Advantage plans.

Insider UK

Glasgow biopharmaceuticals firm hires new chief executive

University spin-out takes on new leadership as it looks towards international growth

Investors Business Daily

Vertex Stock Topples As Investors Seek Clearer Vision Of Future Despite Huge Profit Beat

Vertex Pharmaceuticals' fourth-quarter sales divided analysts Wednesday as VRTX stock toppled on a lack of near-term catalysts.

1 … 58 59 60 61

People

Joe Biden

66,399 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.